维生素D2(Ergocalciferol) - 药物靶点：VDR_在研适应症：低钙血症，高磷酸盐尿，骨软化_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(3β,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol、(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol、(5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol

+ [17]

靶点

VDR

作用方式

激动剂

作用机制

VDR激动剂(维生素D受体激动剂)

治疗领域

遗传病与畸形内分泌与代谢疾病皮肤和肌肉骨骼疾病+ [1]

在研适应症

低钙血症高磷酸盐尿骨软化+ [3]

非在研适应症-

原研机构

SS Pharmaceuticals

在研机构

葵花药业集团股份有限公司Esjay Pharma LLC

非在研机构-

权益机构

江西天之海药业股份有限公司

广西梧州中恒集团股份有限公司

重庆莱美药业股份有限公司

最高研发阶段批准上市

首次获批日期

美国 (1941-01-11),

甲状旁腺功能减退症低磷血症佝偻病

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C28H44O

InChIKeyMECHNRXZTMCUDQ-RKHKHRCZSA-N

CAS号50-14-6

关联

120

项与维生素D2 相关的临床试验

NCT07670611

/ Recruiting临床4期IIT

Accelerated Correction of Vitamin D Deficiency in Cholestatic Children: a Comparative Trial of Vitamin D2 Monotherapy vs Combination Therapy With Calcitriol

The goal of this clinical trial is to learn whether adding calcitriol to vitamin D2 can improve vitamin D deficiency in children with cholestasis and chronic liver disease. Cholestasis is a condition in which bile flow is reduced, which can make it difficult for the body to absorb and process vitamin D. The study will also learn about the safety of using vitamin D2 together with calcitriol.
The main questions it aims to answer are:
* Does vitamin D2 plus calcitriol increase blood 25-hydroxyvitamin D (25-OHD) levels more than vitamin D2 alone after 3 months of treatment?
* Does vitamin D2 plus calcitriol help more children reach an adequate vitamin D level by 3 and 6 months?
* What medical problems, especially high calcium or high phosphorus levels, occur during treatment?
Researchers will compare children who receive vitamin D2 alone with children who receive vitamin D2 plus calcitriol to see which treatment improves vitamin D levels more effectively and safely.
Participants will:
* Take vitamin D2 alone or vitamin D2 plus calcitriol as assigned by randomization
* Visit the clinic for study assessments at the start of the study, at 3 months, and at 6 months
* Have blood tests to measure vitamin D levels, calcium, phosphorus, parathyroid hormone, liver function, and other safety markers
* Have their treatment reviewed at 3 months; participants whose vitamin D level remains low may have their treatment adjusted according to the study plan
* Bring back medication packages so researchers can check how regularly the study medicines were taken

开始日期2026-04-28

申办/合作机构-

NCT07366450

/ Not yet recruitingN/AIIT

Safety and Efficacy of High-Intensity Loading Dose Versus Standard Weekly Dosing of Ergocalciferol (Vitamin D2) for Vitamin D Normalization in Patients With Newly Diagnosed Aggressive Non-Hodgkin Lymphoma: A Randomized, Open-Label, Controlled Trial

The goal of this clinical trial is to evaluate whether a high-intensity loading dose of ergocalciferol (vitamin D2) can normalize blood vitamin D levels more rapidly and safely than standard weekly dosing in patients with newly diagnosed aggressive non-Hodgkin lymphoma. The study will also assess the safety of both dosing strategies.
The main questions it aims to answer are:
* Does a high-intensity loading dose of ergocalciferol lead to faster normalization of serum 25-hydroxyvitamin D levels compared with standard weekly dosing?
* Are there differences in safety and adverse events between the two dosing strategies?
Researchers will compare a high-intensity loading dose regimen of ergocalciferol with a standard weekly dosing regimen to determine differences in vitamin D normalization and safety outcomes.
Participants will:
* Be randomly assigned to receive either a high-intensity loading dose or a standard weekly dose of ergocalciferol (vitamin D2)
* Receive standard first-line immunochemotherapy for aggressive non-Hodgkin lymphoma
* Have blood tests to monitor vitamin D levels, calcium, phosphate, and safety parameters at scheduled visits
* Be followed for treatment response, survival outcomes, and adverse events during and after therapy

开始日期2026-02-01

申办/合作机构

Phramongkutklao College of Medicine

ChiCTR2600121935

/ RecruitingN/AIIT

A Study on the Efficacy of Vitamin D Supplementation in Adolescents with Unipolar Depression

开始日期2025-09-01

申办/合作机构

南方医科大学南方医院

100 项与维生素D2 相关的临床结果

登录后查看更多信息

100 项与维生素D2 相关的转化医学

登录后查看更多信息

100 项与维生素D2 相关的专利（医药）

登录后查看更多信息

3,499

项与维生素D2 相关的文献（医药）

2026-07-01·FOOD CHEMISTRY

Green and sustainable dual-pathway strategies for high-efficiency photoconversion of ergosterol to vitamin D₂ from agaricus bisporus

Article

作者: Yu, Jiahao ; Shen, Mofei ; Feng, Simin ; Tang, Yan ; Lin, Yang ; Shao, Ping

The conversion of ergosterol to vitamin D₂ (VD₂) in Agaricus bisporus is still limited by low efficiency. This study integrates a particle size-regulated powder photoconversion pathway and natural deep eutectic solvent (NADES) integrated extraction-photoconversion pathway to achieve a high VD₂ yield. In the powder pathway, combining UV-B irradiation with a median particle size of 130-140 μm maximized VD₂ yield, reaching 2.59% by balancing optical penetration depth, light shielding, and the resulting porous cellular structure. In the extract pathway, the menthol-based NADES system was developed to achieve simultaneous high-efficiency ergosterol extraction (85.41% extraction efficiency) and stabilization, as well as ergosterol photoconversion to VD₂ (4.08% yield), attributed to enhanced cell permeability and hydrogen bonding interactions. The NADES system also enhanced the storage stability of ergosterol and VD₂ by 24.79% and 20.53%, respectively, compared to the ethanol during storage. This work provides green and tunable dual-pathway strategies for developing high-value VD₂-enriched products.

2026-07-01·JOURNAL OF MOLECULAR GRAPHICS & MODELLING

In silico screening and molecular dynamics simulations of Epicatechin as an inhibitor of EBV LMP1

Article

作者: Salam, Dayang-Sharyati D A

Epstein-Barr Virus (EBV) Latent Membrane Protein 1 (LMP1) is a critical oncoprotein and a high-value target for therapeutics against EBV-associated malignancies. This study employed an integrated in silico approach-combining virtual screening, molecular docking, 250 ns all-atom Molecular Dynamics (MD) simulations in a lipid bilayer, and ADMET prediction-to identify potent LMP1 inhibitors among nutraceutical compounds. Virtual screening of over 700 compounds led to the selection of five top ligands for MD analysis against the full-length LMP1 protein. MD simulations revealed a crucial divergence from static docking, with Epicatechin and Vitamin D2 emerging as the potential stable binders, targeting the protein's C-Terminal Activation Region (CTAR) and Transmembrane Domain (TMD). Epicatechin was predicted as the most thermodynamically favourable binder, exhibiting the strongest total binding free energy (ΔTOTAL = -29.07 ± 1.72 kcal/mol), supported by stable hydrogen bond formation with the key oncogenic residues GLU_335 and GLU_336. Comparatively, Vitamin D2 has better compact and structurally stable complex (lowest Rgyr). Crucially, ADMET analysis provided the clinical filter pending experimental confirmation. While Ginkgolide-B showed superior ADME parameters, its major liability as a strong CYP3A4 inhibitor limited its clinical viability. In contrast, Epicatechin potentially offered a favourable balance: strong binding thermodynamics paired with a superior metabolic profile (minimal CYP inhibition). These results strongly suggest that common nutraceuticals, particularly Epicatechin, provide promising, safer, and chemically tractable scaffolds for the development of multi-target small-molecule inhibitors against EBV latency proteins. This work underscores the potential of nutraceuticals in anti-EBV strategies, supporting multi-target approaches for EBV-related diseases.

2026-05-05·Journal of Applied Laboratory Medicine

Comparison of a Reformulated Automated Vitamin D Assay, Its Predecessor, and 2 Contemporary Formulations

Article

作者: Hubbard, Jacqueline A ; Nerenz, Robert D ; Alvarez, Yasel F ; Singh, Ravinder J ; Geno, K Aaron

Abstract:

Background:

Historically, 25-hydroxyvitamin D (25OHD) assays have under- or over-recovered 25-hydroxyvitamin D2 (25OHD2), but assay manufacturers have modified their reagents to address this problem. In this study, we compared the second- and third-generation Roche assays as well as two contemporary offerings from Diasorin and Beckman against liquid chromatography–tandem mass spectrometry (LC-MS/MS).

Methods:

We identified 50 remnant serum samples with 25OHD concentrations from across the analytical range of the second-generation Roche assay. To increase 25OHD2 representation, we identified 25 additional samples from individuals prescribed high-dose vitamin D2 supplements. We tested samples on Roche assays and circulated to laboratories performing Beckman and Diasorin 25OHD assays. We tested samples by LC-MS/MS to obtain concentrations for 25OHD2 and 25-hydroxyvitamin D3.

Results:

Mean overall bias for each assay was 5.1 ng/mL or less against the LC-MS/MS measurement; mean proportional bias was 8.7% to 12.1%. Some individual specimens had much larger bias. 25OHD2 was under-recovered on average, but the bias for the third-generation Roche assay represents a significant improvement over the previous assay, and mean bias for current generation assays was no worse than −3.2 ng/mL. In most cases, clinical classification by automated assay values agreed with clinical classification by LC-MS/MS; where present, disagreements occurred near classification thresholds.

Conclusions:

Automated 25OHD assays continue to improve, and 25OHD2 recovery no longer appears to be a significant concern for the assays evaluated here. All assays evaluated were adequate for clinical classification of vitamin D nutritional status and are suitable for routine use, including in patients prescribed high-dose vitamin D2.

103

项与维生素D2 相关的新闻（医药）

2026-07-28

·米内网

【火热】中药龙头出手了，2800万入局19亿大品种

精彩内容日前，中恒集团公告称，公司控股子公司莱美药业以2800万元受让江西天之海持有的维生素D2软胶囊批文（国药准字H36021226）。米内网数据显示，2025年中国三大终端六大市场维生素D2软胶囊销售额突破19亿元。维生素D2软胶囊是一种用于预防或治疗维生素D缺乏相关疾病的膳食补充剂或药物。其主要成分为麦角钙化醇（维生素D2），通过调节钙磷代谢、促进骨骼健康发挥作用，常用于佝偻病、骨软化症、骨质疏松等病症的辅助治疗。米内网数据显示，维生素D2软胶囊已被纳入国家医保甲类目录，近年来在中国三大终端六大市场（统计范围详见本文末）的销售额均以两位数的增速持续增长，2025年突破19亿元，同比增长超30%；2026年一季度超过5亿元，同比增长超40%。近年来中国三大终端六大市场维生素D2软胶囊销售情况（单位：万元）来源：米内网格局数据库目前国内已有8家企业拥有维生素D2软胶囊的生产批文。从2026年一季度厂家格局看，南京海鲸药业以超50%的市场份额领跑，大连水产药业以近40%的市场份额紧接其后，江西天之海药业以超5%的市场份额排位第三。在2026年一季度维生素类（化药）TOP5产品中，维生素D滴剂稳居榜首，且近年来市场份额稳步提升；维生素D2软胶囊、注射用多种维生素(12)依次位列第二、第三，均较2025年提升1个位次。 2026Q1中国三大终端六大市场维生素类（化药）TOP5产品来源：米内网格局数据库中恒集团表示，本次交易完成后，将进一步丰富公司产品线，有助于拓展业务领域，实现协议产品从生产到销售的全链条整合，更加灵活应对市场变化，有利于巩固和扩大产品市场及权益份额，提升公司整体市场竞争力。中恒集团成立于1993年，2000年在上交所上市，目前拥有200余个药品（以产品名称计）的生产批文，其中有130余个为中成药，包括注射用血栓通(冻干)、中华跌打丸、炎见宁片等20余个独家品种（含独家剂型）。目前仅中恒集团拥有生产批文的中成药来源：米内网中国上市药品（MID）数据库注：米内网《中国三大终端六大市场药品竞争格局》，统计范围：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至7月28日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com 稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

专利侵权

2026-07-27

·启星医药

医药BD每周资讯 2026年7月第4周（第179期）

行业资讯 NEWS 发布时间：2026年7月27日和誉医药与礼来签署战略研究合作及授权协议同源康医药授予齐鲁制药EGFR-TKI制剂中国大陆独占许可并获4亿元股权投资 Argenx以约22亿美元收购Forte Biosciences 莱美药业以2800万元受让天之海药业维生素D₂软胶囊上市许可及全球商业权益 Scancell Holdings与Neuphoria Therapeutics达成全股合并，寻求纳斯达克上市和誉医药/礼来 2026年7月24日，和誉医药（Abbisko）宣布与礼来（Eli Lilly）签署战略研究合作及授权协议，双方将围绕多个疾病靶点开展创新药研发合作，潜在总金额高达19亿美元，另加阶梯式销售分成。根据协议，和誉将依托其早期药物发现平台、创新研发体系及丰富开发经验，围绕礼来选定的疾病靶点开展新药项目的发现与早期开发活动；和誉将获得首付款，并有资格在达成开发、监管及商业化里程碑后获得进一步付款。从战略角度看，礼来是全球研发效率和资本实力最强的大型药企之一，2026年以来已执行多笔大型收购和合作，持续通过外部创新补强管线；与和誉的合作则聚焦更早期的发现阶段，体现了礼来对和誉小分子药物发现平台能力的认可。同源康医药/齐鲁制药 2026年7月21日，同源康医药（02410.HK）宣布与齐鲁制药达成许可授权及战略合作协议，授予齐鲁制药TY-9591（高选择性不可逆EGFR-TKI）在中国大陆地区的独占许可，覆盖原料药开发生产及商业化；同时齐鲁制药以4亿元人民币战略入股同源康医药，获得14.26%股权。交易总金额为27.6亿元人民币，包括4亿元股权投资、3亿元首付款和最高20.6亿元里程碑付款。TY-9591的新药上市申请已被CDE受理并纳入优先审评。TY-9591作为第三代EGFR-TKI，对标奥希替尼等已验证的重磅品种，国内市场空间广阔；齐鲁制药拥有强大的肿瘤销售网络和仿制药/创新药商业化经验，是理想的国内合作伙伴。对同源康而言，高首付加股权投资可显著改善现金流并验证公司估值，为后续管线的全球开发提供资金。但在7月22日，汇宇制药公告称：自己才是同源康TY-9591的全国独家总代理。早在今年2月，汇宇制药和同源康已经正式签订了协议，首付款项1.5亿元。目前汇宇制药和同源康均已向当地法院提起诉讼。 Argenx/Forte 2026年7月27日，荷兰免疫学公司Argenx宣布和Forte Biosciences达成最终收购协议，Argenx 将以每股77美元的现金收购Forte Biosciences，将其自免药物FB102纳入产品组合，总股权价值约为22亿美元。FB102是一种同类首创的抗CD122抗体，具有双重作用机制，可同时作用IL-2和IL-15，与仅靶向IL-15 的疗法相比，它可能提供更广泛的免疫通路调节。该疗法的机制旨在降低致病性T细胞的活性，同时保留调节性T细胞。该抗体在治疗白癜风和乳糜泻方面已显示出早期潜力，并有望用于治疗多种自身免疫性疾病。近期，Forte Biosciences公布了该药物治疗白癜风的1b期临床试验的积极数据，显示出具有统计学意义的治疗获益。Argenx收购的关键驱动因素正是基于该候选药物积极的研究数据。除了乳糜泻和白癜风之外，FB102还有潜力用于治疗斑秃和其他自身免疫性疾病，这使其具备了作为潜在“pipeline-in-a-product ”的优势。莱美药业/天之海药业 2026年7月23日，莱美药业（300006.SZ）公告以2800万元人民币受让江西天之海药业股份有限公司持有的维生素D₂软胶囊（国药准字H36021226，规格0.25mg）药品注册批文及全球范围内全部商业和市场权益，不含莱美医药已有的全国总代理权。该产品用于预防或治疗维生素D缺乏相关疾病，2025年全终端医院销售额约17.66亿元。交易需国家药监局审批。这是一笔典型的上市许可持有人（MAH）权益转让，属于国内医药工业常见的品种权益交易。对莱美药业而言，以2800万元获得一个年销售额近18亿元的大品种全球权益，若后续能整合生产和渠道资源，有望显著增厚业绩。对天之海药业而言，出让非核心品种可回笼资金并聚焦主业。从行业角度看，随着MAH制度深化和集采常态化，国内药企之间的品种权益转让、批文交易和商业权益整合将持续活跃，此类交易虽然单笔金额不大，但反映了产业资源整合和产能优化的趋势。 Scancell/Neuphoria 2026年7月23日，Scancell Holdings plc（AIM:SCLP）宣布与Neuphoria Therapeutics Inc.（NASDAQ:NEUP）达成全股合并协议，交易未披露具体对价，附带最高8900万美元的股权和债务融资承诺。合并后公司将以Scancell名义运营，并寻求在纳斯达克上市，股票代码SCLT。Scancell股东将持有合并后公司85.5%股权，Neuphoria股东持有14.5%。融资将用于推进Scancell的iSCIB1+（晚期黑色素瘤主动免疫疗法）注册性III期试验。从战略角度分析，这是一笔典型的英国Biotech借道美国上市公司实现纳斯达克升级的交易：Scancell通过合并Neuphoria获得美国上市平台和更广阔的资本市场入口，同时Neuphoria股东获得Scancell的核心资产和控制权溢价。iSCIB1+作为主动免疫疗法，通过激活患者自身免疫系统攻击癌细胞，在晚期黑色素瘤领域具有差异化定位。以上信息来源于公开渠道，由启星医药汇总整理。如需合作请扫上方二维码联系客服业务合作邮箱 bd@cstarboutique.com 深圳启星医药科技有限公司专注于医药资产交易及国际化合作的精品投行

2026-07-27

·药筛

一张维生素D批文，2800万

一张维生素D批文，价值2800万。上周，中恒集团发布公告，控股子公司重庆莱美，以2800万元，买下江西天之海的维生素D₂软胶囊批文（国药准字 H36021226，规格 0.25mg（1 万单位），价格是2800万元。此前，重庆莱美是这个品种的全国总代理，协议期是到2033年7月。维生素D2软胶囊，是预防或治疗维生素D缺乏相关疾病基础用药，常用于佝偻病、骨软化症、骨质疏松等病症。目前是医保甲类、基药。总计16张批文，8个企业。目前虽然已有参比制剂，但没有任何企业过评价。这个品种，医院市场的年销售额超过10亿元，一半来自南京海鲸药业，大连水产占40%，莱美收购的江西天之海药业占4%。一个老批文，能卖上这个价格，不算低。另外，想要买同类批文朋友，可以联系客服。摩熵药筛小程序2999元及以上年度会员朋友，可以联系客服，获取十二批国采分析数据。已包含报名企业目录

100 项与维生素D2 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00187	维生素D2	A11CC01	DB00153

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
低钙血症	中国	葵花药业集团股份有限公司	1982-01-01
高磷酸盐尿	中国	葵花药业集团股份有限公司	1982-01-01
骨软化	中国	葵花药业集团股份有限公司	1982-01-01
甲状旁腺功能减退症	美国	Esjay Pharma LLC	1941-01-11
低磷血症	美国	Esjay Pharma LLC	1941-01-11
佝偻病	美国	Esjay Pharma LLC	1941-01-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05673980 (Pubmed \| Sci Rep)	N/A	新型冠状病毒感染 serum 25-hydroxyvitamin D (25(OH)D) \| C-reaction protein (CRP) \| complement component C1q ... 更多	228	Vitamin D2	襯築鬱積簾鹽構糧簾夢(鬱壓簾蓋醖憲鑰糧衊艱) = 簾憲觸糧淵積觸鹽繭蓋鏇窪鑰鏇網範艱鏇蓋製 (簾鹹鹽膚夢築蓋廠壓蓋 ) 更多	不佳	2024-09-03
				vitamin D (Non-intervention)	襯築鬱積簾鹽構糧簾夢(鬱壓簾蓋醖憲鑰糧衊艱) = 鑰醖積艱襯鏇網網選憲鏇窪鑰鏇網範艱鏇蓋製 (簾鹹鹽膚夢築蓋廠壓蓋 ) 更多
NCT03046927 (PCR, CTgov)	临床2/3期	1型糖尿病	48	Ergocalciferol (Ergocalciferol)	遞觸構憲遞憲襯艱獵餘(簾積鏇壓淵醖積觸齋製) = 觸糧廠鏇齋築衊壓範廠觸襯夢願窪鹽簾鑰憲憲 (獵襯憲網範廠築艱襯範, 0.28) 更多	-	2024-07-10
				Placebo (Placebo)	遞觸構憲遞憲襯艱獵餘(簾積鏇壓淵醖積觸齋製) = 鏇繭積遞夢膚膚膚繭製觸襯夢願窪鹽簾鑰憲憲 (獵襯憲網範廠築艱襯範, 0.31) 更多
NCT01568255 (CTgov)	临床4期	维生素D缺乏症 \| 肌肉疾患	11	Ergocalciferol (Vitamin D Treatment)	蓋鬱夢觸窪餘構簾積製 = 構願醖餘繭積壓鹹壓觸艱範網鹽願鹽淵簾餘蓋 (鏇壓壓鹹鹽壓顧鏇鏇範, 窪繭齋醖齋齋鬱製衊構 ~ 廠顧顧願遞衊簾衊網鑰) 更多	-	2021-06-10
				Placebo (Placebo Group)	蓋鬱夢觸窪餘構簾積製 = 鏇網夢鏇鹹鑰醖鹽積醖艱範網鹽願鹽淵簾餘蓋 (鏇壓壓鹹鹽壓顧鏇鏇範, 選鬱衊簾繭簾糧蓋壓蓋 ~ 觸鏇鏇醖餘鑰廠鹽窪艱) 更多
NCT01173848 (UPGRADE, CTgov)	临床3期	慢性肾病	19	Ergocalciferol (Vitamin D2)	獵膚蓋積夢積淵觸醖壓 = 願積窪積廠構糧膚齋鏇願廠構醖衊範衊遞遞顧 (鏇鬱鑰繭壓築構夢廠構, 憲襯壓衊鬱範遞壓願構 ~ 簾鏇鬱觸蓋鑰獵構鏇憲)	-	2017-04-04
				cholecalciferol (Vitamin D3)	獵膚蓋積夢積淵觸醖壓 = 鏇糧餘糧鬱糧淵築鹹鬱願廠構醖衊範衊遞遞顧 (鏇鬱鑰繭壓築構夢廠構, 顧繭襯遞糧鑰餘餘顧鏇 ~ 艱鹹糧淵襯遞簾網齋窪)
NCT01426347 (CTgov)	N/A	维生素D缺乏症 \| 类风湿关节炎	139	Placebo sugar pill+Ergocalciferol (Placebo Group)	齋積壓範顧範遞憲蓋鑰(夢獵糧繭窪顧淵衊構遞) = 壓鬱衊顧築製簾鏇膚構繭積鑰蓋夢襯遞鬱獵願 (觸襯簾鏇衊壓蓋觸構鬱, 1.5) 更多	-	2017-03-20
				Ergocalciferol (Ergocalciferol)	齋積壓範顧範遞憲蓋鑰(夢獵糧繭窪顧淵衊構遞) = 積築願範製網窪鬱範醖繭積鑰蓋夢襯遞鬱獵願 (觸襯簾鏇衊壓蓋觸構鬱, 1.3) 更多
NCT01848236 (Pubmed \| J Clin Endocrinol Metab)	N/A	维生素D缺乏症	-	Vitamin D2	顧繭廠鏇鏇網鏇憲鏇廠(憲簾顧蓋蓋壓積繭鏇鑰) = 壓醖夢網積壓構蓋鏇淵範網繭醖願製觸獵願鹹 (餘齋鏇齋壓鑰願簾選蓋 ) 更多	-	2016-08-01
				Vitamin D3	顧繭廠鏇鏇網鏇憲鏇廠(憲簾顧蓋蓋壓積繭鏇鑰) = 願襯觸膚獵夢糧製齋淵範網繭醖願製觸獵願鹹 (餘齋鏇齋壓鑰願簾選蓋 ) 更多
NCT01633853 (CTgov)	临床4期	慢性肾病-矿物质和骨骼疾病 \| 维生素D缺乏症	204	1,25(OH)2 Vit D3 (1,25(OH)2 Vitamin D3)	餘艱壓積選網夢範醖鹹(鹹廠鏇獵鬱觸選簾選選) = 範築艱鹽鬱夢範膚鏇鏇範構築鹽願醖選選憲壓 (鬱網糧觸鏇簾製齋鏇顧, 0.14) 更多	-	2016-02-15
				Vitamin D2 (Vitamin D2 Treatment)	蓋獵積艱壓範餘夢夢鹽 = 襯築鏇壓膚鹹廠積糧衊膚醖夢壓鹹觸遞積膚膚 (顧艱鹽鬱鬱醖窪築艱願, 艱製遞鹹壓窪範顧糧願 ~ 淵觸鹹顧膚醖憲築構鬱)
NCT00892099 (CTgov)	N/A	终末期肾脏病 \| 感染	105	Ergocalciferol (High Dose Ergocalciferol)	糧顧夢簾蓋艱製襯淵鏇(淵觸醖觸鑰鹽淵憲網構) = 簾鏇顧鏇簾繭簾觸鑰鑰繭艱願醖齋築顧齋餘廠 (鑰遞夢網構齋簾簾鑰遞, 2.3) 更多	-	2015-06-08
				Ergocalciferol (Low Dose Ergocalciferol)	糧顧夢簾蓋艱製襯淵鏇(淵觸醖觸鑰鹽淵憲網構) = 糧製簾窪壓壓積願選廠繭艱願醖齋築顧齋餘廠 (鑰遞夢網構齋簾簾鑰遞, 2.4) 更多
NCT01217840 (CTgov)	N/A	炎症 \| 肥胖	40	Ergocalciferol (Vitamin D)	糧壓鹽鑰範壓鬱築壓膚(鹽憲鹹醖廠膚遞範襯廠) = 夢淵壓壓選夢範衊獵願窪築憲糧膚鏇憲鬱遞範 (構遞願獵網鏇觸襯範顧, 1.4) 更多	-	2015-03-02
				Placebo (Placebo)	糧壓鹽鑰範壓鬱築壓膚(鹽憲鹹醖廠膚遞範襯廠) = 壓獵餘餘襯憲鑰遞選獵窪築憲糧膚鏇憲鬱遞範 (構遞願獵網鏇觸襯範顧, 2.6) 更多
NCT00742235 (CTgov)	N/A	维生素D缺乏症	99	25-OH vitamin D+ergocalciferol	夢膚觸夢艱廠選構遞齋(繭願醖鹹鬱選獵構糧窪) = 鬱積蓋簾廠鹹網蓋淵淵願衊鑰網醖鏇願獵襯願 (淵淵鬱範齋範簾糧膚衊, 347) 更多	-	2013-11-11